MEASuRE: Metreleptin Effectiveness And Safety Registry
Study Identifier:
AEGR-734-400
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Generalized Lipodystrophy
- Partial Lipodystrophy
Study Drug
- Drug: Metreleptin
Date
Oct 2016 - Oct 2031
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
- Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
- Patients who provide a written consent
- Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply
Exclusion Criteria
- • Patients currently treated with an investigational agent as part of a clinical trial
Healthy Volunteers
No
Protocol Summary
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Study Locations
Location
Status
Location
University Alabama at Birmingham
Birmingham, Alabama, United States, 40506
Status
Terminated
Location
City of Hope
Duarte, California, United States, 91010
Status
Terminated
Location
Atlanta Diabetes Associates
Atlanta, Georgia, United States, 30318
Status
Active, not recruiting
Location
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Status
Recruiting
Location
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas, United States, 66160
Status
Recruiting
Location
Children's Hospital of New Orleans/LSU Health Sciences Center
New Orleans, Louisiana, United States, 70118
Status
Completed
Go to page